GlassScriptPhysician profile
Kavitha Tellakula
NPI 1952577850
$8,119.22
in general payments reported to CMS, 2019-2025
42 companies · $962 in 2025
The $962 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $863 · 2020: $958 · 2021: $2,645 · 2022: $704 · 2023: $1,035 · 2024: $953 · 2025: $962.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,950.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,950.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $1,200.00 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $995.56 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $771.40 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $735.33 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $711.81 | 2019-2025 | Vraylar, Ubrelvy, Synthroid |
| Takeda Pharmaceuticals U.S.A., INC. | $468.98 | 2019-2025 | Trintellix |
| Amgen INC. | $441.53 | 2019-2025 | Repatha, Otezla, Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $327.17 | 2019-2023 | Jardiance |
| Pfizer INC. | $259.59 | 2019-2025 | |
| Amarin Pharma, INC. | $223.71 | 2019-2021 | |
| Glaxosmithkline, LLC. | $222.94 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Merck Sharp & Dohme LLC | $222.30 | 2019-2024 | Belsomra, Lagevrio, Gardasil |
| Astellas Pharma US INC | $147.65 | 2019-2025 | Veozah, Myrbetriq |
| Cequr Corporation | $122.30 | 2024-2025 | Cequr Simplicity |
| Janssen Pharmaceuticals, INC | $120.37 | 2020-2025 | Spravato |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $118.32 | 2023-2025 | Cologuard Collection Kit |
| Ascensia Diabetes Care US INC. | $114.46 | 2023 | |
| Dynavax Technologies Corporation | $86.68 | 2021-2024 | Heplisav-B |
| Esperion Therapeutics, INC. | $85.76 | 2021-2023 | Nexletol |
| Corcept Therapeutics | $71.77 | 2024 | Korlym |
| Vivus LLC | $59.62 | 2019-2023 | Qsymia |
| Sanofi-Aventis U.S. LLC | $59.40 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $57.52 | 2020-2023 | Livalo, Seglentis |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $49.02 | 2024-2025 | Caplyta |
| Eisai INC. | $45.19 | 2020-2021 | |
| Beta Bionics, INC. | $41.25 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Tandem Diabetes Care, INC. | $37.81 | 2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Idorsia Pharmaceuticals US INC | $37.31 | 2023-2024 | Quviviq |
| Arbor Pharmaceuticals, INC. | $32.00 | 2021 | |
| Genentech USA, INC. | $27.91 | 2020-2021 | |
| Inspire Medical Systems, INC. | $25.55 | 2025 | Inspire |
| Embecta Corp. | $23.91 | 2024 | |
| Allergan, INC. | $22.99 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $21.85 | 2025 | |
| Sequel Med Tech, LLC | $21.35 | 2025 | Twiist |
| Axsome Therapeutics, INC. | $21.24 | 2025 | Auvelity |
| Paratek Pharmaceuticals, INC. | $16.92 | 2021 | |
| Linus Health, INC. | $15.08 | 2024 | Core Cognitive Evaluation |
| Horizon Therapeutics Plc | $14.33 | 2020 | |
| Abbott Laboratories | $14.32 | 2022 | |
| Insulet Corporation | $13.88 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.14 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kavitha Tellakula listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.